Search results
1 lut 2021 · Anti-Melanoma Differentiation-Associated gene 5 (MDA-5) Dermatomyositis (MDA5, DM) is a recently identified subtype of myositis characteristically associated with Rapidly Progressive Interstitial Lung Disease (RP-ILD) and unique cutaneous features.
- Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features ...
Anti-MDA5 dermatomyositis is a rare systemic autoimmune...
- Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical ...
Anti-melanoma differentiation-associated protein 5 (MDA5)...
- Understanding and managing anti-MDA 5 dermatomyositis ... - PubMed
Anti-Melanoma Differentiation-Associated gene 5 (MDA-5)...
- New therapies in anti-MDA5 antibody-positive dermatomyositis
Purpose of review: This review focuses on treatments for...
- Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features ...
6 gru 2023 · Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) is a subtype of dermatomyositis with a poor prognosis that typically presents...
20 paź 2021 · Anti-MDA5 dermatomyositis is a rare systemic autoimmune disease, historically described in Japanese patients with clinically amyopathic dermatomyositis and life-threatening rapidly progressive interstitial lung disease.
Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) is a subtype of dermatomyositis. Although the aetiology and pathology remain unclear, increasing evidence suggests that viral infection is a potential trigger of MDA5-DM.
Anti-Melanoma Differentiation-Associated gene 5 (MDA-5) Dermatomyositis (MDA5, DM) is a recently identified subtype of myositis characteristically associated with Rapidly Progressive Interstitial Lung Disease (RP-ILD) and unique cutaneous features.
27 mar 2021 · Anti-Melanoma Differentiation-Associated gene 5 (MDA-5) Dermatomyositis (MDA5, DM) is a recently identified subtype of myositis characteristically associated with Rapidly Progressive Interstitial Lung Disease (RP-ILD) and unique cutaneous features.
1 sty 2024 · Purpose of review: This review focuses on treatments for anti-MDA5 antibody-positive dermatomyositis (MDA5-DM), which is a subgroup of dermatomyositis and characterized by frequent rapidly progressive interstitial lung disease and the high mortality rate.
